Heart failure is no longer just about weakened pumping—a fundamental shift in medical understanding reveals that preserved pump function with impaired filling affects millions more patients than previously recognized. This condition, known as heart failure with preserved ejection fraction (HFpEF), now represents approximately 50% of all heart failure cases, yet remains dramatically underdiagnosed in clinical practice.
The core challenge lies in detection complexity. Unlike traditional heart failure where ejection fraction drops below 40%, HFpEF patients maintain normal pumping strength above 50% while experiencing diastolic dysfunction—the heart muscle stiffens, preventing proper filling between beats. Recent diagnostic advances include stress echocardiography protocols and natriuretic peptide biomarker refinements that can identify subtle filling abnormalities during exercise when resting tests appear normal.
This diagnostic evolution carries profound implications for cardiovascular medicine and patient outcomes. HFpEF predominantly affects older adults, women, and those with multiple comorbidities including diabetes, obesity, and hypertension—populations where symptoms like shortness of breath are often attributed to aging or other conditions. The mortality rates mirror those of reduced ejection fraction heart failure, yet treatment approaches differ significantly. While traditional heart failure medications focus on reducing cardiac workload, HFpEF management emphasizes controlling underlying metabolic conditions and optimizing diastolic function. The recognition that half of heart failure patients require fundamentally different therapeutic strategies represents a paradigm shift that could reshape clinical protocols and improve outcomes for millions who currently receive suboptimal care due to misdiagnosis or delayed recognition.